Guardian.co.uk, www.guardian.co.uk, March 2, 2011, by Julia Kollewe
AstraZeneca pharmaceutical company has joined its French rival, Sanofi-aventis, and the Universities of Cambridge and Lausanne in the More Medicines for Tuberculosis (MM4TB) consortium to develop new drugs for successful and shorter TB treatment. The consortium also includes the universities of Pavia, Italy, and Uppsala, Sweden, in addition to 19 other research groups from 13 countries. The consortium is led by TB expert Professor Stewart Cole of the École Polytechnique Fédérale de Lausanne, and will be funded by a €16million (US $22,215, 369) European Union grant. AstraZeneca will share its compounds and expertise, and research will be conducted at London hospitals and the John Innes Center, England, as well as in Russia, India, and South Africa. The aim is to have 10 to 20 compounds in the pipeline to develop two to three successful TB drugs.
No comments:
Post a Comment